The drug, Journavx by Vertex Pharmaceuticals, blocks pain signals to the brain, making it nonaddictive. By Gina Kolata The Food and Drug Administration approved a new medication Thursday to treat ...

For the last quarter century, one of the world’s most capable drug developers toiled to make a new, non-addictive kind of painkiller. The journey was fittingly excruciating. Pain, as Vertex ...

The Food and Drug Administration approved the pill from Vertex Pharmaceuticals for acute pain that often occurs after surgery or injuries. It's the first new pharmaceutical approach to treating pain ...

Vertex Pharmaceuticals (NASDAQ: VRTX) has long been known as the company to turn to for life-saving cystic fibrosis (CF) ...

Journavx is a non-opioid drug that prevents peripheral nerves from sending pain signals to the brain. Journavx is one of three recently approved drugs in Vertex Pharmaceuticals' product lineup.

(Vertex Pharmaceuticals via AP) Opioids reduce pain by binding to receptors in the brain that receive nerve signals from different parts of the body. Those chemical interactions also give rise to ...

The U.S. Food and Drug Administration (FDA) approved Thursday a new type of prescription pain medication for moderate to severe acute pain for adults.

This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. The movement to steer pain treatment away from opioids ...

For the first time in decades, a new class of painkiller has been approved by the US Food and Drug Administration (FDA).

Opioids reduce pain by binding to receptors in the brain that receive nerve signals from different parts of the body. Those chemical interactions also give rise to opioids’ addictive effects. Vertex’s ...

Shares of Vertex Pharmaceuticals (NASDAQ ... It prevents pain signals from reaching the brain. A lack of activity in the brain makes Journavx a non-addictive solution for all types of moderate ...

Vertex just won approval for a drug to treat ... does this at the level of the peripheral nervous system and not in the brain, offering patients a strong safety profile. The U.S. Food and Drug ...